Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Eithne Costello

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0104-8992; OpenAlex author ID A5007485514, A5139997774, A5158626670. Sources: OpenAlex.

Their work

Papers
90 (first author 1, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
299
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 4 papers · 2014: 4 papers · 2015: 6 papers · 2016: 12 papers · 2017: 7 papers · 2018: 12 papers · 2019: 3 papers · 2020: 4 papers · 2021: 7 papers · 2022: 3 papers · 2023: 7 papers · 2024: 2 papers · 2025: 7 papers · 2026: 5 papers

Papers 50 of 90

  1. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592↗
  2. Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines. Co-author DOI 10.1016/j.xpro.2026.104904↗
  3. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  4. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Last author DOI 10.1093/jnci/djaf345↗
  5. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  6. Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes. Last author DOI 10.1001/jamanetworkopen.2025.38031↗
  7. Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer. Last author DOI 10.1016/j.semcancer.2025.02.009↗
  8. From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. Co-author DOI 10.1016/j.semcancer.2025.03.004↗
  9. Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancr… Co-author DOI 10.1016/j.semcancer.2025.05.001↗
  10. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  11. Prevalence of New-Onset Diabetes in Patients Undergoing Pancreatic Surgery and the Association of Glucose Dysregulation With Complications in Pancreatic Cancer. Last author DOI 10.1097/as9.0000000000000584↗
  12. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  13. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  14. Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection. Co-author DOI 10.1371/journal.pcbi.1012408↗
  15. Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs. Last author DOI 10.1007/s13105-021-00857-2↗
  16. The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. Co-author DOI 10.1007/s13105-022-00899-0↗
  17. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  18. Where the metabolome meets the microbiome for pancreatic cancer detection. First author DOI 10.1016/j.xcrm.2023.101011↗
  19. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  20. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  21. Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. Co-author DOI 10.3390/cimb45030164↗
  22. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Last author DOI 10.1016/j.ebiom.2021.103802↗
  23. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early de… Last author DOI 10.1136/bmjopen-2022-068010↗
  24. Recent advances in understanding pancreatic cancer. Co-author DOI 10.12703/r/11-9↗
  25. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  26. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  27. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  28. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  29. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  30. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  31. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  32. Early detection of pancreatic cancer. Last author DOI 10.1016/s2468-1253(19)30416-9↗
  33. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  34. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  35. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. Co-author DOI 10.1371/journal.pmed.1003489↗
  36. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  37. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  38. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  39. Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. Co-author DOI 10.1002/ijc.31087↗
  40. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  41. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  42. Therapeutic developments in pancreatic cancer: current and future perspectives. Co-author DOI 10.1038/s41575-018-0005-x↗
  43. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  44. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  45. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  46. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Co-author DOI 10.1097/sla.0000000000002088↗
  47. A metabolomics-based biomarker signature discriminates pancreatic cancer from chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2016-313665↗
  48. S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes. Last author DOI 10.1186/s12885-018-5161-4↗
  49. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Co-author DOI 10.18632/oncotarget.26034↗
  50. F1F0-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation. Co-author DOI 10.3389/fphys.2018.00833↗

Closest collaborators

The 25 strongest of 299 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William Greenhalf · 54 shared papers, 2011–2026 · strength 4.56
  2. Christopher Michael Halloran · 21 shared papers, 2012–2026 · strength 2.37
  3. John P. Neoptolemos · 40 shared papers, 2011–2026 · strength 2.30
  4. Lucy S. Oldfield · 12 shared papers, 2016–2026 · strength 2.04
  5. Paula Ghaneh · 16 shared papers, 2014–2026 · strength 1.48
  6. Daniel H. Palmer · 14 shared papers, 2014–2025 · strength 1.19
  7. Stephen P. Pereira · 11 shared papers, 2015–2026 · strength 1.15
  8. Daniele Campa · 9 shared papers, 2011–2025 · strength 0.97
  9. Núria Malats · 12 shared papers, 2015–2024 · strength 0.90
  10. Aldo Scarpa · 15 shared papers, 2013–2024 · strength 0.90
  11. Francisco X. Real · 12 shared papers, 2015–2024 · strength 0.87
  12. Martyn Charles Stott · 4 shared papers, 2022–2025 · strength 0.83
  13. Jorg H. Kleeff · 12 shared papers, 2015–2024 · strength 0.83
  14. Lawrence N. Barrera · 5 shared papers, 2016–2026 · strength 0.82
  15. Thilo Hackert · 9 shared papers, 2016–2026 · strength 0.80
  16. Christoph W. Michalski · 9 shared papers, 2013–2026 · strength 0.78
  17. Markus Wolfgang Büchler · 15 shared papers, 2011–2021 · strength 0.75
  18. Tatjana Crnogorac‐Jurcevic · 10 shared papers, 2015–2024 · strength 0.71
  19. Alfredo Carrato · 10 shared papers, 2015–2024 · strength 0.70
  20. Irena Stefanova · 3 shared papers, 2025 · strength 0.67
  21. Thomas Mathias Gress · 9 shared papers, 2016–2024 · strength 0.63
  22. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  23. Luis Muñoz‐Bellvís · 8 shared papers, 2017–2024 · strength 0.58
  24. J. Enrique Domínguez‐Muñoz · 8 shared papers, 2017–2024 · strength 0.58
  25. Bo Kong · 8 shared papers, 2017–2024 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.